Heparin sodium Rx
Generic Name and Formulations:
Heparin sodium 1000, 5000, 10000units; per mL; IV or SC inj; preservative-free or preserved with benzyl alcohol.
Various generic manufacturers
Indications for Heparin sodium:
Adults and Children:
See full labeling. Individualize based on lab results and disease.
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT). Hypersensitivity to pork products. When blood coagulation testing is not feasible. Uncontrolled active bleeding state, except when due to disseminated intravascular coagulation.
IM use not recommended. Confirm choice of correct strength prior to administration. Monitor for any degree of thrombocytopenia; discontinue if platelet count falls <100000/mm3 or if recurrent thrombosis develops; evaluate for HIT and HITT; if needed, give alternative anticoagulant. Major bleeding or conditions with increased risk of hemorrhage (eg, bacterial endocarditis, severe hypertension, surgery, hemophilia, hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy, ulcerative lesions, continuous GI tube drainage, menstruation, liver disease with impaired hemostasis). Monitor blood coagulation tests (discontinue if test is unduly prolonged or if hemorrhage occurs), platelets, hematocrit during therapy. Heparin resistance (monitor). History of allergy. Not interchangeable (unit-for-unit) with low molecular weight heparins. Women >60yrs of age. Elderly. Neonates/infants (gasping syndrome due to benzyl alcohol), pregnancy, nursing mothers: use preservative-free formulations.
Potentiated by anticoagulants (eg, dicumerol, warfarin), antiplatelets (eg, salicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, celecoxib, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists including abciximab, eptifibatide, tirofiban) and others; caution. Antagonized by digitalis, tetracyclines, nicotine, antihistamines, IV nitroglycerin. Potentiated by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency; reduce heparin dose.
Hemorrhage, thrombocytopenia, HIT and HITT, inj site irritation, hypersensitivity reactions, increased aminotransferase levels.
Formerly known under the brand names Panheparin, Lipo-Hepin, Liquaemin.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Rapid Cycling Bipolar Disorder Associated With ADHD and Female Gender
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Symptom Trajectories Vary According to Language Development in Autism
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children